{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,30]],"date-time":"2026-04-30T18:47:57Z","timestamp":1777574877906,"version":"3.51.4"},"reference-count":49,"publisher":"Elsevier BV","license":[{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2019,5,1]],"date-time":"2019-05-01T00:00:00Z","timestamp":1556668800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100000041","name":"American Diabetes Association","doi-asserted-by":"publisher","award":["1-18-IBS-172"],"award-info":[{"award-number":["1-18-IBS-172"]}],"id":[{"id":"10.13039\/100000041","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R41EY027665-01A1"],"award-info":[{"award-number":["R41EY027665-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R21EY027065"],"award-info":[{"award-number":["R21EY027065"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R01EY027749-01A1"],"award-info":[{"award-number":["R01EY027749-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["R24EY028764-01A1"],"award-info":[{"award-number":["R24EY028764-01A1"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100000002","name":"National Institutes of Health","doi-asserted-by":"publisher","award":["P30-EY014801"],"award-info":[{"award-number":["P30-EY014801"]}],"id":[{"id":"10.13039\/100000002","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100001818","name":"Research to Prevent Blindness","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100001818","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100001809","name":"National Natural Science Foundation of China","doi-asserted-by":"publisher","award":["81670841"],"award-info":[{"award-number":["81670841"]}],"id":[{"id":"10.13039\/501100001809","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Experimental Eye Research"],"published-print":{"date-parts":[[2019,5]]},"DOI":"10.1016\/j.exer.2019.03.009","type":"journal-article","created":{"date-parts":[[2019,3,21]],"date-time":"2019-03-21T01:42:02Z","timestamp":1553132522000},"page":"57-64","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":15,"special_numbering":"C","title":["Function-first ligandomics for ocular vascular research and drug target discovery"],"prefix":"10.1016","volume":"182","author":[{"given":"Xin","family":"Rong","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hong","family":"Tian","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Liu","family":"Yang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Wei","family":"Li","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"key":"10.1016\/j.exer.2019.03.009_bib2","first-page":"182","article-title":"Clinical correlates of common corneal neovascular diseases: a literature review","volume":"8","author":"Abdelfattah","year":"2015","journal-title":"Int. J. Ophthalmol."},{"key":"10.1016\/j.exer.2019.03.009_bib3","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1007\/s10555-017-9663-3","article-title":"The biology of uveal melanoma","volume":"36","author":"Amaro","year":"2017","journal-title":"Cancer Metastasis Rev."},{"key":"10.1016\/j.exer.2019.03.009_bib4","doi-asserted-by":"crossref","first-page":"197","DOI":"10.1016\/j.bbrc.2009.06.010","article-title":"Efficient identification of phosphatidylserine-binding proteins by ORF phage display","volume":"386","author":"Caberoy","year":"2009","journal-title":"Biochem. Biophys. Res. Commun."},{"key":"10.1016\/j.exer.2019.03.009_bib5","doi-asserted-by":"crossref","first-page":"653","DOI":"10.1177\/1087057109335679","article-title":"Can phage display be used as a tool to functionally identify endogenous eat-me signals in phagocytosis?","volume":"14","author":"Caberoy","year":"2009","journal-title":"J. Biomol. Screen"},{"key":"10.1016\/j.exer.2019.03.009_bib6","doi-asserted-by":"crossref","first-page":"74","DOI":"10.1002\/jmr.983","article-title":"Efficient identification of tubby-binding proteins by an improved system of T7 phage display","volume":"23","author":"Caberoy","year":"2010","journal-title":"J. Mol. Recognit."},{"key":"10.1016\/j.exer.2019.03.009_bib7","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1186\/s40942-017-0084-9","article-title":"Retinal and choroidal angiogenesis: a review of new targets","volume":"3","author":"Cabral","year":"2017","journal-title":"Int J Retina Vitreous"},{"key":"10.1016\/j.exer.2019.03.009_bib8","doi-asserted-by":"crossref","first-page":"465","DOI":"10.1038\/nrclinonc.2009.94","article-title":"Adverse effects of anticancer agents that target the VEGF pathway","volume":"6","author":"Chen","year":"2009","journal-title":"Nat. Rev. Clin. Oncol."},{"key":"10.1016\/j.exer.2019.03.009_bib9","doi-asserted-by":"crossref","first-page":"2229","DOI":"10.2337\/diabetes.48.11.2229","article-title":"Increased renal expression of vascular endothelial growth factor (VEGF) and its receptor VEGFR-2 in experimental diabetes","volume":"48","author":"Cooper","year":"1999","journal-title":"Diabetes"},{"key":"10.1016\/j.exer.2019.03.009_bib47","doi-asserted-by":"crossref","first-page":"1193","DOI":"10.1056\/NEJMoa1414264","article-title":"Aflibercept, bevacizumab, or ranibizumab for diabetic macular edema","volume":"372","author":"Diabetic Retinopathy Clinical Research Network","year":"2015","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.03.009_bib10","first-page":"533","article-title":"Current perspectives on ranibizumab","volume":"9","author":"Dedania","year":"2015","journal-title":"Clin. Ophthalmol."},{"key":"10.1016\/j.exer.2019.03.009_bib11","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1258\/la.2010.010090","article-title":"Single dose streptozotocin-induced diabetes: considerations for study design in islet transplantation models","volume":"45","author":"Deeds","year":"2011","journal-title":"Lab. Anim"},{"key":"10.1016\/j.exer.2019.03.009_bib12","doi-asserted-by":"crossref","first-page":"100","DOI":"10.3928\/23258160-20170130-02","article-title":"An overview of the fovista and rinucumab trials and the fate of anti-PDGF medications","volume":"48","author":"Dunn","year":"2017","journal-title":"Ophthalmic Surg Lasers Imaging Retina"},{"key":"10.1016\/j.exer.2019.03.009_bib13","doi-asserted-by":"crossref","first-page":"1932","DOI":"10.1038\/srep01932","article-title":"Intravital analysis of vascular permeability in mice using two-photon microscopy","volume":"3","author":"Egawa","year":"2013","journal-title":"Sci. Rep."},{"key":"10.1016\/j.exer.2019.03.009_bib14","doi-asserted-by":"crossref","first-page":"311","DOI":"10.1016\/j.critrevonc.2015.01.012","article-title":"Bevacizumab: a dose review","volume":"94","author":"Falk","year":"2015","journal-title":"Crit. Rev. Oncol. Hematol."},{"key":"10.1016\/j.exer.2019.03.009_bib15","doi-asserted-by":"crossref","first-page":"5 47 41","DOI":"10.1002\/0471141755.ph0547s70","article-title":"Streptozotocin-induced diabetic models in mice and rats","volume":"70","author":"Furman","year":"2015","journal-title":"Curr Protoc Pharmacol"},{"key":"10.1016\/j.exer.2019.03.009_bib16","first-page":"161","article-title":"Angiogenic factors as potential drug target: efficacy and limitations of anti-angiogenic therapy","volume":"1846","author":"Gacche","year":"2014","journal-title":"Biochim. Biophys. Acta"},{"key":"10.1016\/j.exer.2019.03.009_bib17","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1167\/tvst.5.4.11","article-title":"Optical coherence tomography angiography in mice: comparison with confocal scanning laser microscopy and fluorescein angiography","volume":"5","author":"Giannakaki-Zimmermann","year":"2016","journal-title":"Transl Vis Sci Technol"},{"key":"10.1016\/j.exer.2019.03.009_bib18","first-page":"356","article-title":"The streptozotocin-induced diabetic nude mouse model: differences between animals from different sources","volume":"61","author":"Graham","year":"2011","journal-title":"Comp. Med."},{"key":"10.1016\/j.exer.2019.03.009_bib19","doi-asserted-by":"crossref","first-page":"1897","DOI":"10.1056\/NEJMoa1102673","article-title":"Ranibizumab and bevacizumab for neovascular age-related macular degeneration","volume":"364","author":"Group","year":"2011","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.03.009_bib20","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ophtha.2016.09.012","article-title":"Incidence and growth of geographic atrophy during 5 Years of comparison of age-related macular degeneration treatments trials","volume":"124","author":"Grunwald","year":"2017","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.03.009_bib21","doi-asserted-by":"crossref","first-page":"63","DOI":"10.1097\/IIO.0b013e3181a8db88","article-title":"Retinal vascular occlusion syndromes","volume":"49","author":"Haymore","year":"2009","journal-title":"Int. Ophthalmol. Clin."},{"key":"10.1016\/j.exer.2019.03.009_bib22","doi-asserted-by":"crossref","first-page":"1445","DOI":"10.1016\/S0140-6736(13)60178-6","article-title":"Retinopathy of prematurity","volume":"382","author":"Hellstrom","year":"2013","journal-title":"Lancet"},{"key":"10.1016\/j.exer.2019.03.009_bib23","author":"Kiel"},{"key":"10.1016\/j.exer.2019.03.009_bib24","doi-asserted-by":"crossref","first-page":"e33","DOI":"10.1016\/j.ophtha.2008.02.013","article-title":"The effect of topical bevacizumab on corneal neovascularization","volume":"115","author":"Kim","year":"2008","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.03.009_bib25","doi-asserted-by":"crossref","first-page":"e0127904","DOI":"10.1371\/journal.pone.0127904","article-title":"Hepatoma-derived growth factor-related protein-3 is a novel angiogenic factor","volume":"10","author":"LeBlanc","year":"2015","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.03.009_bib26","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1084\/jem.20161802","article-title":"Secretogranin III as a disease-associated ligand for antiangiogenic therapy of diabetic retinopathy","volume":"214","author":"LeBlanc","year":"2017","journal-title":"J. Exp. Med."},{"key":"10.1016\/j.exer.2019.03.009_bib27","doi-asserted-by":"crossref","first-page":"2212","DOI":"10.1016\/j.ophtha.2014.05.015","article-title":"Intravitreal bevacizumab versus laser treatment in type 1 retinopathy of prematurity: report on fluorescein angiographic findings","volume":"121","author":"Lepore","year":"2014","journal-title":"Ophthalmology"},{"key":"10.1016\/j.exer.2019.03.009_bib28","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1038\/nprot.2008.172","article-title":"Direct labeling and visualization of blood vessels with lipophilic carbocyanine dye DiI","volume":"3","author":"Li","year":"2008","journal-title":"Nat. Protoc."},{"key":"10.1016\/j.exer.2019.03.009_bib29","doi-asserted-by":"crossref","first-page":"1090","DOI":"10.1161\/ATVBAHA.115.306964","article-title":"Mitochondrial reactive oxygen species mediate lysophosphatidylcholine-induced endothelial cell activation","volume":"36","author":"Li","year":"2016","journal-title":"Arterioscler. Thromb. Vasc. Biol."},{"key":"10.1016\/j.exer.2019.03.009_bib30","doi-asserted-by":"crossref","first-page":"636","DOI":"10.1016\/j.drudis.2018.01.013","article-title":"Ligandomics: a paradigm shift in biological drug discovery","volume":"23","author":"Li","year":"2018","journal-title":"Drug Discov. Today"},{"key":"10.1016\/j.exer.2019.03.009_bib31","doi-asserted-by":"crossref","first-page":"641","DOI":"10.1101\/gad.186965.112","article-title":"Complexity in the signaling network: insights from the use of targeted inhibitors in cancer therapy","volume":"26","author":"Logue","year":"2012","journal-title":"Genes Dev."},{"key":"10.1016\/j.exer.2019.03.009_bib32","doi-asserted-by":"crossref","first-page":"237","DOI":"10.3389\/fgene.2015.00237","article-title":"Quantitative affinity purification mass spectrometry: a versatile technology to study protein-protein interactions","volume":"6","author":"Meyer","year":"2015","journal-title":"Front. Genet."},{"key":"10.1016\/j.exer.2019.03.009_bib33","first-page":"5632634","article-title":"Switch to aflibercept in diabetic macular edema patients unresponsive to previous anti-VEGF therapy","author":"Mira","year":"2017","journal-title":"J.ophthalmol."},{"key":"10.1016\/j.exer.2019.03.009_bib34","doi-asserted-by":"crossref","first-page":"1323","DOI":"10.1097\/IAE.0000000000000500","article-title":"Switching treatment for neovascular Age-related macular degeneration from bevacizumab to ranibizumab: who is likely to benefit from the switch?","volume":"35","author":"Moisseiev","year":"2015","journal-title":"Retina"},{"key":"10.1016\/j.exer.2019.03.009_bib35","doi-asserted-by":"crossref","first-page":"e0202156","DOI":"10.1371\/journal.pone.0202156","article-title":"Intravitreal pro-inflammatory cytokines in non-obese diabetic mice: modelling signs of diabetic retinopathy","volume":"13","author":"Mugisho","year":"2018","journal-title":"PLoS One"},{"key":"10.1016\/j.exer.2019.03.009_bib36","first-page":"51","article-title":"Crosstalk coregulation mechanisms of G protein-coupled receptors and receptor tyrosine kinases","volume":"332","author":"Natarajan","year":"2006","journal-title":"Methods Mol. Biol."},{"key":"10.1016\/j.exer.2019.03.009_bib37","doi-asserted-by":"crossref","first-page":"227","DOI":"10.1177\/0883073815587943","article-title":"Retinoblastoma","volume":"31","author":"Ortiz","year":"2016","journal-title":"J. Child Neurol."},{"key":"10.1016\/j.exer.2019.03.009_bib38","doi-asserted-by":"crossref","first-page":"1057","DOI":"10.7150\/ijbs.7502","article-title":"The vascular endothelium and human diseases","volume":"9","author":"Rajendran","year":"2013","journal-title":"Int. J. Biol. Sci."},{"key":"10.1016\/j.exer.2019.03.009_bib39","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1056\/NEJMoa054481","article-title":"Ranibizumab for neovascular age-related macular degeneration","volume":"355","author":"Rosenfeld","year":"2006","journal-title":"N. Engl. J. Med."},{"key":"10.1016\/j.exer.2019.03.009_bib40","doi-asserted-by":"crossref","first-page":"302","DOI":"10.2174\/1874192401004010302","article-title":"The endothelium and its role in regulating vascular tone","volume":"4","author":"Sandoo","year":"2010","journal-title":"Open Cardiovasc. Med. J."},{"key":"10.1016\/j.exer.2019.03.009_bib41","doi-asserted-by":"crossref","first-page":"19","DOI":"10.1038\/nrd.2016.230","article-title":"A comprehensive map of molecular drug targets","volume":"16","author":"Santos","year":"2017","journal-title":"Nat. Rev. Drug Discov."},{"key":"10.1016\/j.exer.2019.03.009_bib42","first-page":"2337","article-title":"Retinal vascular permeability suppression by topical application of a novel VEGFR2\/Src kinase inhibitor in mice and rabbits","volume":"118","author":"Scheppke","year":"2008","journal-title":"J. Clin. Investig."},{"key":"10.1016\/j.exer.2019.03.009_bib43","doi-asserted-by":"crossref","first-page":"125","DOI":"10.1159\/000438969","article-title":"Neovascular age-related macular degeneration","volume":"55","author":"Shao","year":"2016","journal-title":"Dev. Ophthalmol."},{"key":"10.1016\/j.exer.2019.03.009_bib44","doi-asserted-by":"crossref","first-page":"37","DOI":"10.3389\/fimmu.2016.00037","article-title":"Ocular immune privilege and transplantation","volume":"7","author":"Taylor","year":"2016","journal-title":"Front. Immunol."},{"key":"10.1016\/j.exer.2019.03.009_bib45","doi-asserted-by":"crossref","first-page":"93","DOI":"10.1007\/s00281-011-0285-5","article-title":"Endothelium--role in regulation of coagulation and inflammation","volume":"34","author":"van Hinsbergh","year":"2012","journal-title":"Semin. Immunopathol."},{"key":"10.1016\/j.exer.2019.03.009_bib46","doi-asserted-by":"crossref","first-page":"479","DOI":"10.1007\/s10456-017-9557-6","article-title":"Pathogenic role and therapeutic potential of pleiotrophin in mouse models of ocular vascular disease","volume":"20","author":"Wang","year":"2017","journal-title":"Angiogenesis"},{"key":"10.1016\/j.exer.2019.03.009_bib48","first-page":"3202","article-title":"Immune privilege is extended, then withdrawn, from allogeneic tumor cell grafts placed in the subretinal space","volume":"40","author":"Wenkel","year":"1999","journal-title":"Investig. Ophthalmol. Vis. Sci."},{"key":"10.1016\/j.exer.2019.03.009_bib49","doi-asserted-by":"crossref","first-page":"16012","DOI":"10.1038\/nrdp.2016.12","article-title":"Diabetic retinopathy","volume":"2","author":"Wong","year":"2016","journal-title":"Nat Rev Dis Primers"},{"key":"10.1016\/j.exer.2019.03.009_bib50","first-page":"789","article-title":"Sensitive blood-retinal barrier breakdown quantitation using Evans blue","volume":"42","author":"Xu","year":"2001","journal-title":"Investig. Ophthalmol. Vis. Sci."}],"container-title":["Experimental Eye Research"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518309278?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0014483518309278?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2026,4,28]],"date-time":"2026-04-28T19:23:51Z","timestamp":1777404231000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0014483518309278"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2019,5]]},"references-count":49,"alternative-id":["S0014483518309278"],"URL":"https:\/\/doi.org\/10.1016\/j.exer.2019.03.009","relation":{},"ISSN":["0014-4835"],"issn-type":[{"value":"0014-4835","type":"print"}],"subject":[],"published":{"date-parts":[[2019,5]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Function-first ligandomics for ocular vascular research and drug target discovery","name":"articletitle","label":"Article Title"},{"value":"Experimental Eye Research","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.exer.2019.03.009","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}